Givinostat (ITF2357)

Givinostat (ITF2357)はヒストン脱アセチル酵素(HDACs)経口有効阻害剤、 IC50 が 7.5-16 nM.

目録号S2170
4.5 5 1レビュー 4製品表彰状
価格 在庫  
USD 214 In stock
USD 403 In stock
USD 403 In stock
USD 1222 In stock
USD 3112 In stock

Givinostat (ITF2357) 化学構造
分子量: 475.97

品質と確認

カスタマーレビュー(1)

Quality Control & MSDS

製品情報

  • Compare HDAC Inhibitors
    HDAC阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 Givinostat (ITF2357)はヒストン脱アセチル酵素(HDACs)経口有効阻害剤、 IC50 が 7.5-16 nM.
目標 HDAC
IC50 7.5 to 16 nM [1]
In vitro試験 In LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduces the release of TNFα, IL-1α, IL-1β, and IFNγ, with IC50 of 10-25 nM, respectively. Using the combination of IL-12 plus IL-18, ITF2357 reduces IFNγ and IL-6 production with IC50 of 12.5-25 nM, independent of decreased IL-1 or TNFα. [1] ITF2357 is cytotoxic in multiple myeloma (MM) cell lines (RPMI8226, NCI-H929, JJN3, KMS 11, KMS 12, KMS 18, and KMS 20) and acute myelogenous leukemia (AML) cell lines (HL-60, THP-1, U937, KASUMI, KG-1, and TF-1), with IC50 of 200 nM. ITF2357 activates the intrinsic apoptotic pathway, upregulates p21 and downmodulates Bcl-2 and Mcl-1. ITF2357 inhibits the production of IL-6, VEGF, and IFNγ in mesenchymal stromal cells (MSCs) by 80-95%. [2] ITF2357 favors β-cell survival during inflammatory conditions. ITF2357 at concentrations of 25 and 250 nM increases islet cell viability, enhances insulin secretion, inhibits release of MIP-1α and MIP-2, reduces NO production and decreases apoptosis rates. [3]
In vivo試験 ITF2357 (1-10 mg/kg) reduces LPS-induced serum TNFα and IFNγ by more than 50% in mice. Anti-CD3-induced cytokines are not suppressed by ITF2357 in PBMCs in the circulation in mice. In concanavalin-A-induced hepatitis, ITF2357 (1 or 5 mg/kg) significantly reduces liver damage. [1] ITF2357 (10 mg/kg) significantly prolongs survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line. [2] In a mouse model of closed head injury (CHI), ITF2357 (10 mg/kg) improves neurobehavioral recovery, decreases neuronal degeneration, reduces lesion volume, and induces glial apoptosis. [4]
臨床試験 A Phase II clinical trial of ITF2357 in active systemic onset juvenile idiopathic arthritis (SOJIA) has been completed.
特集 An orally active, potent inhibitor of histone deacetylases (HDACs).

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Enzymatic Assay for HDAC Inhibitory Activity of Synthetic Compounds The assay is performed by adding 100 μL substrate (2×105 cpm), 40 μL buffer (50 mM Tris-HCl, pH 8.0, 750 mM NaCl, 5 mM PMSF, 50% glycerol) and 95 μL distilled water to the crude cellular extract (5 μL). ITF2357 (50 μL) is added to test for HDAC inhibition. The mixture is incubated overnight at room temperature and the reaction quenched by adding 50 μL of a solution containing 259 μL 37% HCl and 28 μL acetic acid in 1 mL distilled water. The [3H]acetyl residues released from the substrate are separated by organic extraction with 600 μL of ethyl acetate, 200 μL of the organic phase is added to standard scintillation fluid, and radioactivity is measured by a beta-counter. Inhibition of HDACs is expressed as the concentration inhibiting 50% of the control activity (by comparing the radioactivity of the samples containing inhibitors to that of the control containing cellular crude extract alone).

細胞アッセイ: [1]

細胞系 peripheral blood mononuclear cells (PBMCs)
濃度 1 nM - 1 μM
処理時間 24 hours
方法 After washing, the isolated PBMCs are resuspended in RPMI containing 5% FCS at 5×106/mL, added to a 50-mL conical polypropylene tube, and placed at 4 °C overnight. The PBMCs are resuspended the next morning and added to a 96-well flat microtiter plate (100 μL per well). ITF2357 is then added for inhibition studies, and the plates are incubated at 37 °C for 1 hour, after which the cells are stimulated with LPS or other stimulants in a final volume of 200 μL per well. The supernatants are removed after incubation at 37 °C for 24 hours, and frozen at -80 °C until assayed for cytokines.

動物実験: [1]

動物モデル Mice. For LPS induction of serum cytokines: BALB/c; for anti-CD3-induced cytokines: CD1; for concanavalin A (Con A)-induced acute hepatitis: BALB/c or C57Bl6.
製剤 Dissolved in water
投薬量 0.01-50 mg/kg
管理 By gavage in 100 μL water.
Solubility 30% propylene glycol, 5% Tween 80, 65% D5W, 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
1

参考

化学情報

Download Givinostat (ITF2357) SDF
分子量 475.97
化学式

C24H27N3O4.HCl.H2O

CAS No. 732302-99-7
保管 2年-20℃
6月-80℃in DMSO
別名
溶解度 (25°C) * In vitro DMSO 95 mg/mL (199 mM)
<1 mg/mL (<1 mM)
エタノール 3 mg/mL (6 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (6-((diethylamino)methyl)naphthalen-2-yl)methyl 4-(hydroxycarbamoyl)phenylcarbamate hydrochloride hydrate

研究分野

カスタマーレビュー (1)


Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Givinostat (ITF2357) purchased from Selleck
Method Western blot
Cell Lines
Concentrations 0-10 μM
Incubation Time
Results Increased Histone acetylation in cells treated with ITF2357 was observed.

製品表彰状 (4)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related HDAC 阻害剤

  • Resminostat

    Resminostat dose-dependently and selectively inhibits HDAC1/3/6 with IC50 of 42.5 nM/50.1 nM/71.8 nM, less potent to HDAC8 with IC50 of 877 nM.

  • RGFP966

    RGFP966 is a HDAC inhibitor, with an IC50 of 0.08μM for HDAC3, exhibits > 200-fold selectivity over other HDAC.

  • RG2833 (RGFP109)

    RG2833 (RGFP109) is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

  • Nexturastat A

    Nexturastat A is a potent and selective HDAC inhibitor with IC50 of 5 nM, >190-fold selectivity over other HDACs.

  • Panobinostat (LBH589)

    Panobinostat (LBH589)は、MOLT-4とReh細胞のための新しい幅広いスペクトルHDAC阻害剤で、IC50 がそれぞれ 5 と 20 nMになる。Phase 4

  • Vorinostat (SAHA, MK0683)

    Vorinostat (SAHA, MK0683)ボリノスタット(SAHA)は、86nM未満のIC50による強力なクラスIおよびIIヒストン脱アセチル化酵素(HDAC)阻害剤です。

    Features:Vorinostat是广谱HDAC活性抑制剂,抑制I和II类酶 。

  • Entinostat (MS-275)

    Entinostat (MS-275)は、HDAC1とHDAC3のHDAC阻害剤で、IC50 がそれぞれ 0.51 μM と 1.7 μMです。

  • Trichostatin A (TSA)

    Trichostatin A (TSA) は、HDAC阻害剤で、IC50 が ~1.8 nM。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は、強力なヒストン脱アセチル化酵素1と2つの(HDAC1とHDAC2)阻害剤で、 IC50 がそれぞれ 36 nM と 47 nMです。

    Features:Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103)は、強力なヒストン脱アセチル化酵素(HDAC)(HDAC 1、HDAC 2とHDAC 3のためのクラスI阻害剤)で、 IC50 がそれぞれ 0.15 μM、 0.29 μM 、1.66 μMになる。

最近見られたアイテム

Tags: Givinostat (ITF2357)を買う | Givinostat (ITF2357)供給者 | Givinostat (ITF2357)を購入する | Givinostat (ITF2357)費用 | Givinostat (ITF2357)生産者 | オーダーGivinostat (ITF2357) | Givinostat (ITF2357)代理店
お問い合わせ